Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice

Molecular Therapy

Volumn 25, Issue 1, 2017, Pages 165-180

  Kölling, Malte ^a   Kaucsar, Tamas ^c   Schauerte, Celina ^a   Hübner, Anika ^a   Dettling, Angela ^a   Park, Joon Keun ^a   Busch, Martin ^d   Wulff, Xaver ^d   Meier, Matthias ^a   Scherf, Kristian ^a   Bukosza, Nóra ^c   Szénási, Gábor ^c   Godó, Mária ^c   Sharma, Amit ^a   Heuser, Michael ^a   Hamar, Peter ^c   Bang, Claudia ^a   Haller, Hermann ^a   Thum, Thomas ^a,b   Lorenzen, Johan M ^a,e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

cell cycle regulators; diabetic nephropathy; mesangial hypertrophy; microRNA; miR 21; podocyte motility; TGF

Indexed keywords

MICRORNA 21; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; CDC25A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE 6; MICRORNA; MIRN21 MICRORNA, MOUSE; PROTEIN TYROSINE PHOSPHATASE;

ADULT; AGED; ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL EXPANSION; CELL INFILTRATION; CELL LOSS; CELL MOTILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; FIBROSING ALVEOLITIS; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY HYPERTROPHY; MACROPHAGE; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; PATHOGENESIS; PODOCYTE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; CELL CYCLE CHECKPOINT; CELL MOTION; CLUSTER ANALYSIS; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; FIBROSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GLOMERULUS; INFLAMMATION; METABOLISM; PATHOLOGY; RNA INTERFERENCE;

ANIMALS; CDC25 PHOSPHATASES; CELL CYCLE CHECKPOINTS; CELL MOVEMENT; CLUSTER ANALYSIS; CYCLIN-DEPENDENT KINASE 6; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; INFLAMMATION; KIDNEY GLOMERULUS; MESANGIAL CELLS; MICE; MICRORNAS; PODOCYTES; RNA INTERFERENCE;

EID: 85016258889     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2016.08.001     Document Type: Article

References (44)

1. 1 Raptis, A.E., Viberti, G., Pathogenesis of diabetic nephropathy. Exp. Clin. Endocrinol. Diabetes 109:Suppl 2 (2001), S424–S437.
2. 2 Fineberg, D., Jandeleit-Dahm, K.A., Cooper, M.E., Diabetic nephropathy: diagnosis and treatment. Nat. Rev. Endocrinol. 9 (2013), 713–723.
3. 3 Sarnak, M.J., Levey, A.S., Schoolwerth, A.C., Coresh, J., Culleton, B., Hamm, L.L., McCullough, P.A., Kasiske, B.L., Kelepouris, E., Klag, M.J., et al., American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108 (2003), 2154–2169.
4. 4 Lorenzen, J.M., Haller, H., Thum, T., MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat. Rev. Nephrol. 7 (2011), 286–294.
5. 5 Kato, M., Zhang, J., Wang, M., Lanting, L., Yuan, H., Rossi, J.J., Natarajan, R., MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc. Natl. Acad. Sci. USA 104 (2007), 3432–3437.
6. 6 Lai, J.Y., Luo, J., O'Connor, C., Jing, X., Nair, V., Ju, W., Randolph, A., Ben-Dov, I.Z., Matar, R.N., Briskin, D., et al. MicroRNA-21 in glomerular injury. J. Am. Soc. Nephrol. 26 (2015), 805–816.
7. 7 Gomez, I.G., MacKenna, D.A., Johnson, B.G., Kaimal, V., Roach, A.M., Ren, S., Nakagawa, N., Xin, C., Newitt, R., Pandya, S., et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J. Clin. Invest. 125 (2015), 141–156.
8. 8 Osipova, J., Fischer, D.C., Dangwal, S., Volkmann, I., Widera, C., Schwarz, K., Lorenzen, J.M., Schreiver, C., Jacoby, U., Heimhalt, M., et al. Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study. J. Clin. Endocrinol. Metab. 99 (2014), E1661–E1665.
9. 9 Yamamoto, T., Nakamura, T., Noble, N.A., Ruoslahti, E., Border, W.A., Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. USA 90 (1993), 1814–1818.
10. 10 Wolf, G., Sharma, K., Chen, Y., Ericksen, M., Ziyadeh, F.N., High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-beta. Kidney Int. 42 (1992), 647–656.
11. 11 Hoffmann, I., Draetta, G., Karsenti, E., Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 13 (1994), 4302–4310.
12. 12 Lukas, J., Bartkova, J., Bartek, J., Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol. Cell. Biol. 16 (1996), 6917–6925.
13. 13 Lorenzen, J.M., Schauerte, C., Hübner, A., Kölling, M., Martino, F., Scherf, K., Batkai, S., Zimmer, K., Foinquinos, A., Kaucsar, T., et al. Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis. Eur. Heart J. 36 (2015), 2184–2196.
14. 14 Wolf, G., Chen, S., Ziyadeh, F.N., From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54 (2005), 1626–1634.
15. 15 Nadarajah, R., Milagres, R., Dilauro, M., Gutsol, A., Xiao, F., Zimpelmann, J., Kennedy, C., Wysocki, J., Batlle, D., Burns, K.D., Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int. 82 (2012), 292–303.
16. 16 Putta, S., Lanting, L., Sun, G., Lawson, G., Kato, M., Natarajan, R., Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J. Am. Soc. Nephrol. 23 (2012), 458–469.
17. 17 Lin, C.L., Lee, P.H., Hsu, Y.C., Lei, C.C., Ko, J.Y., Chuang, P.C., Huang, Y.T., Wang, S.Y., Wu, S.L., Chen, Y.S., et al. MicroRNA-29a promotion of nephrin acetylation ameliorates hyperglycemia-induced podocyte dysfunction. J. Am. Soc. Nephrol. 25 (2014), 1698–1709.
18. 18 Chen, H.Y., Zhong, X., Huang, X.R., Meng, X.M., You, Y., Chung, A.C., Lan, H.Y., MicroRNA-29b inhibits diabetic nephropathy in db/db mice. Mol. Ther. 22 (2014), 842–853.
19. 19 Wang, B., Komers, R., Carew, R., Winbanks, C.E., Xu, B., Herman-Edelstein, M., Koh, P., Thomas, M., Jandeleit-Dahm, K., Gregorevic, P., et al. Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J. Am. Soc. Nephrol. 23 (2012), 252–265.
20. 20 Wang, B., Jha, J.C., Hagiwara, S., McClelland, A.D., Jandeleit-Dahm, K., Thomas, M.C., Cooper, M.E., Kantharidis, P., Transforming growth factor-β1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney Int. 85 (2014), 352–361.
21. 21 Park, J.T., Kato, M., Lanting, L., Castro, N., Nam, B.Y., Wang, M., Kang, S.W., Natarajan, R., Repression of let-7 by transforming growth factor-β1-induced Lin28 upregulates collagen expression in glomerular mesangial cells under diabetic conditions. Am. J. Physiol. Renal Physiol. 307 (2014), F1390–F1403.
22. 22 Park, J.T., Kato, M., Yuan, H., Castro, N., Lanting, L., Wang, M., Natarajan, R., FOG2 protein down-regulation by transforming growth factor-β1-induced microRNA-200b/c leads to Akt kinase activation and glomerular mesangial hypertrophy related to diabetic nephropathy. J. Biol. Chem. 288 (2013), 22469–22480.
23. 23 Wang, B., Koh, P., Winbanks, C., Coughlan, M.T., McClelland, A., Watson, A., Jandeleit-Dahm, K., Burns, W.C., Thomas, M.C., Cooper, M.E., Kantharidis, P., miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes 60 (2011), 280–287.
24. 24 Dey, N., Das, F., Mariappan, M.M., Mandal, C.C., Ghosh-Choudhury, N., Kasinath, B.S., Choudhury, G.G., MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J. Biol. Chem. 286 (2011), 25586–25603.
25. 25 McClelland, A.D., Herman-Edelstein, M., Komers, R., Jha, J.C., Winbanks, C.E., Hagiwara, S., Gregorevic, P., Kantharidis, P., Cooper, M.E., miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin. Sci. 129 (2015), 1237–1249.
26. 26 Chau, B.N., Xin, C., Hartner, J., Ren, S., Castano, A.P., Linn, G., Li, J., Tran, P.T., Kaimal, V., Huang, X., et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci. Transl. Med., 4, 2012, 121ra18.
27. 27 Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456 (2008), 980–984.
28. 28 Zhong, X., Chung, A.C., Chen, H.Y., Dong, Y., Meng, X.M., Li, R., Yang, W., Hou, F.F., Lan, H.Y., miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 56 (2013), 663–674.
29. 29 Zhong, X., Chung, A.C., Chen, H.Y., Meng, X.M., Lan, H.Y., Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J. Am. Soc. Nephrol. 22 (2011), 1668–1681.
30. 30 Wolf, G., Molecular mechanisms of diabetic mesangial cell hypertrophy: a proliferation of novel factors. J. Am. Soc. Nephrol. 13 (2002), 2611–2613.
31. 31 Kanwar, Y.S., Wada, J., Sun, L., Xie, P., Wallner, E.I., Chen, S., Chugh, S., Danesh, F.R., Diabetic nephropathy: mechanisms of renal disease progression. Exp. Biol. Med. (Maywood) 233 (2008), 4–11.
32. 32 Wolf, G., Shankland, S.J., P27Kip1: the “rosebud” of diabetic nephropathy?. J. Am. Soc. Nephrol. 14 (2003), 819–822.
33. 33 Wang, P., Zou, F., Zhang, X., Li, H., Dulak, A., Tomko, R.J. Jr., Lazo, J.S., Wang, Z., Zhang, L., Yu, J., microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res. 69 (2009), 8157–8165.
34. 34 Abdel-Wahab, N., Weston, B.S., Roberts, T., Mason, R.M., Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J. Am. Soc. Nephrol. 13 (2002), 2437–2445.
35. 35 Nagai, K., Matsubara, T., Mima, A., Sumi, E., Kanamori, H., Iehara, N., Fukatsu, A., Yanagita, M., Nakano, T., Ishimoto, Y., et al. Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int. 68 (2005), 552–561.
36. 36 Sekizuka, K., Tomino, Y., Sei, C., Kurusu, A., Tashiro, K., Yamaguchi, Y., Kodera, S., Hishiki, T., Shirato, I., Koide, H., Detection of serum IL-6 in patients with diabetic nephropathy. Nephron 68 (1994), 284–285.
37. 37 Suzuki, D., Miyazaki, M., Naka, R., Koji, T., Yagame, M., Jinde, K., Endoh, M., Nomoto, Y., Sakai, H., In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 44 (1995), 1233–1238.
38. 38 Lin, J.S., Shi, Y., Peng, H., Shen, X., Thomas, S., Wang, Y., Truong, L.D., Dryer, S.E., Hu, Z., Xu, J., Loss of PTEN promotes podocyte cytoskeletal rearrangement, aggravating diabetic nephropathy. J. Pathol. 236 (2015), 30–40.
39. 39 Xing, L., Liu, Q., Fu, S., Li, S., Yang, L., Liu, S., Hao, J., Yu, L., Duan, H., PTEN Inhibits High Glucose-Induced Phenotypic Transition in Podocytes. J. Cell. Biochem. 116 (2015), 1776–1784.
40. 40 Obad, S., dos Santos, C.O., Petri, A., Heidenblad, M., Broom, O., Ruse, C., Fu, C., Lindow, M., Stenvang, J., Straarup, E.M., et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 43 (2011), 371–378.
41. 41 Gebeshuber, C.A., Kornauth, C., Dong, L., Sierig, R., Seibler, J., Reiss, M., Tauber, S., Bilban, M., Wang, S., Kain, R., et al. Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. Nat. Med. 19 (2013), 481–487.
42. 42 Lorenzen, J.M., Kaucsar, T., Schauerte, C., Schmitt, R., Rong, S., Hübner, A., Scherf, K., Fiedler, J., Martino, F., Kumarswamy, R., et al. MicroRNA-24 antagonism prevents renal ischemia reperfusion injury. J. Am. Soc. Nephrol. 25 (2014), 2717–2729.
43. 43 Dong, Z., Lavrovsky, V., Colburn, N.H., Transformation reversion induced in JB6 RT101 cells by AP-1 inhibitors. Carcinogenesis 16 (1995), 749–756.
44. 44 Sharma, A., Yun, H., Jyotsana, N., Chaturvedi, A., Schwarzer, A., Yung, E., Lai, C.K., Kuchenbauer, F., Argiropoulos, B., Görlich, K., et al. Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling. Leukemia 29 (2015), 157–168.